Soligenix Inc. (NASDAQ: SNGX) reported its 2025 results, emphasizing significant advancements in its rare disease pipeline, particularly the Phase 3 FLASH2 trial of HyBryte (TM) for cutaneous T-cell lymphoma (CTCL). The company expects an interim analysis in Q2 2026 and top-line results in the second half of the year, marking a critical step toward potential regulatory filings. This progress is vital for patients with CTCL, a rare form of non-Hodgkin lymphoma, as HyBryte offers a novel photodynamic therapy using visible light, which may provide a safer treatment alternative.
Additionally, Soligenix highlighted regulatory milestones, including orphan drug designation for dusquetide in Behçet’s Disease. This designation underscores the potential of dusquetide, a first-in-class innate defense regulator, to address an unmet medical need in this rare inflammatory condition. The company is also advancing SGX302 for psoriasis and SGX945 for Behçet’s Disease, expanding its pipeline beyond CTCL.
Financially, Soligenix reported a year-end cash position of approximately $7.9 million. The company continues to explore strategic options to support late-stage development, which is crucial for advancing these programs through clinical trials and toward commercialization. The positive trial updates and regulatory designations could attract partnership opportunities or additional funding.
For more details, the full press release is available at https://ibn.fm/b1p2y. Soligenix is a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs. Its specialized biotherapeutics segment includes HyBryte for CTCL, and it also develops vaccines for public health threats. The company’s progress in 2025 highlights its commitment to addressing rare diseases and the potential for new treatments to reach patients.
